#United States #New York #Faruqi & Faruqi #PEPG #PepGen

Faruqi & Faruqi Calls Attention to Potential Class Action Against PepGen

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced its ongoing investigation into potential claims against PepGen Inc. This move comes as the firm warns investors of the impending deadline to file as lead plaintiffs in a federal securities class action against the company. Set for August 11, 2025, the deadline underscores the necessity for affected investors who may have suffered losses while acquiring PepGen securities between March 7, 2024, and March 3, 2025.

In a statement released on August 9, 2025, Faruqi & Faruqi's senior partner, James (Josh) Wilson, encouraged stakeholders who have faced financial setbacks to reach out and explore their legal options. The firm has built its reputation on advocating for investors and recovering substantial amounts of money for its clients since its establishment in 1995, covering a range of issues pertaining to federal securities laws.

The allegations outlined in the class action suggest that PepGen and its executives may have violated these laws by disseminating false or misleading information about the efficacy and safety of their experimental drug, PGN-EDO51. According to the claims, studies related to PGN-EDO51 did not yield the results that PepGen had led investors to believe, particularly regarding the drug's effectiveness in the CONNECT2 study.

In July 2024, PepGen issued an optimistic press release addressing preliminary positive clinical data from the ongoing CONNECT1 study. However, analysts quickly pointed out that the reported increase in dystrophin was considerably lower than expected, prompting a significant drop of 32.69% in PepGen’s stock price shortly after.

The challenges continued when, in December 2024, the company announced a clinical hold from the FDA concerning its IND application for the CONNECT2 study. This hold indicated potential risks associated with the study, leading to further declines in the stock price as investors processed the bad news. By early 2025, PepGen admitted to safety concerns that made them temporarily halt the CONNECT2 study, further exacerbating investor fears and resulting in additional stock price reductions.

On July 28, 2025, the company ultimately declared its decision to discontinue the development of PGN-EDO51 for DMD, reinforcing investor confidence issues following earlier announcements.

Faruqi & Faruqi is affirming that any investor affected by these developments has options, including participating as lead plaintiffs in the class action. The firm is open to receiving communications from whistleblowers, shareholders, and anyone with relevant information about PepGen's circumstances, thereby fostering a broader investigation.

Potential class members are advised that they do not need to act as lead plaintiffs to benefit from any recovery that may arise from these proceedings. The firm encourages interested individuals to reach out for more information either by visiting their dedicated website or directly contacting partner Josh Wilson.

As the clock ticks down to the deadline, the call for PepGen investors to protect their rights is louder than ever. Faruqi & Faruqi stands ready to assist those looking to pursue their claims as the investigation unfolds.

Conclusion

With the deadline set in the near future, PepGen investors need to remain vigilant and informed regarding their legal rights. Consulting with experienced legal professionals is crucial for navigating these tumultuous waters as the class action develops. Faruqi & Faruqi remains committed to ensuring that investors receive the justice they seek, promoting accountability within the corporate landscape.